Boyle Scott N
Insider CIK 1913897 · CCCC Chief Business Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| CCCC C4 Therapeutics, Inc. | M Exercise | 2026-02-14 | 2026-02-18 | 20,950 | — | $0 | 306,070 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | F Tax w/h | 2026-02-14 | 2026-02-18 | 7,269 | $1.89 | $13.7K | 298,801 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | F Tax w/h | 2026-02-13 | 2026-02-18 | 1,735 | $1.89 | $3.3K | 306,070 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | M Exercise | 2026-02-13 | 2026-02-18 | 5,000 | — | $0 | 307,805 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | A Award | 2026-02-13 | 2026-02-18 | 200,000 | — | $0 | 307,805 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | S Sale | 2025-02-18 | 2025-02-18 | 669 | $3.15 | $2.1K | 107,805 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | A Award deriv | 2025-02-14 | 2025-02-18 | 84,700 | — | $0 | 84,700 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | F Tax w/h | 2025-02-14 | 2025-02-18 | 2,368 | $3.18 | $7.5K | 108,474 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | S Sale | 2025-02-14 | 2025-02-18 | 490 | $3.15 | $1.5K | 110,842 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | A Award | 2025-02-14 | 2025-02-18 | 56,500 | — | $0 | 111,332 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | F Tax w/h | 2025-02-13 | 2025-02-18 | 1,735 | $3.20 | $5.6K | 54,832 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | M Exercise deriv | 2024-11-07 | 2024-11-12 | 3,750 | — | $0 | 10,500 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | M Exercise | 2024-11-07 | 2024-11-12 | 3,750 | — | $0 | 57,669 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | F Tax w/h | 2024-11-07 | 2024-11-12 | 1,102 | $6.04 | $6.7K | 56,567 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | M Exercise deriv | 2024-09-16 | 2024-09-17 | 2,250 | — | $0 | 14,250 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | M Exercise | 2024-09-16 | 2024-09-17 | 2,250 | — | $0 | 54,580 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | F Tax w/h | 2024-09-16 | 2024-09-17 | 661 | $6.36 | $4.2K | 53,919 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | D To issuer deriv | 2024-03-07 | 2024-03-08 | 115,000 | — | $0 | 0 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | A Award deriv | 2024-03-07 | 2024-03-08 | 115,000 | — | $0 | 115,000 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | A Award deriv | 2024-02-14 | 2024-02-15 | 122,800 | — | $0 | 122,800 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | A Award | 2024-02-14 | 2024-02-15 | 27,300 | — | $0 | 52,330 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | F Tax w/h | 2024-02-13 | 2024-02-15 | 1,735 | $6.53 | $11.3K | 25,030 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | A Award deriv | 2023-09-18 | 2023-09-19 | 120,000 | — | $0 | 120,000 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | M Exercise deriv | 2023-08-30 | 2023-08-31 | 2,250 | — | $0 | 16,500 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | M Exercise | 2023-08-30 | 2023-08-31 | 2,250 | — | $0 | 27,426 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | F Tax w/h | 2023-08-30 | 2023-08-31 | 661 | $2.93 | $1.9K | 26,765 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | A Award deriv | 2023-02-13 | 2023-02-15 | 90,000 | — | $0 | 90,000 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | A Award | 2023-02-13 | 2023-02-15 | 20,000 | — | $0 | 25,176 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | M Exercise deriv | 2023-01-30 | 2023-02-01 | 3,750 | — | $0 | 18,750 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | M Exercise | 2023-01-30 | 2023-02-01 | 3,750 | — | $0 | 6,398 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | F Tax w/h | 2023-01-30 | 2023-02-01 | 1,222 | $7.78 | $9.5K | 5,176 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | F Tax w/h | 2022-05-26 | 2022-06-14 | 1,102 | $7.01 | $7.7K | 2,648 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | M Exercise deriv | 2022-05-25 | 2022-05-27 | 3,750 | — | $0 | 22,500 | SEC↗ |
| CCCC C4 Therapeutics, Inc. | M Exercise | 2022-05-25 | 2022-05-27 | 3,750 | — | $0 | 3,750 | SEC↗ |